Testosterone Therapy in Relation to Prostate Cancer in a U.S. Commercial Insurance Claims Database.

ABSTRACT:

Background

We conducted a study to assess whether testosterone therapy (TT) alters prostate cancer risk using a large U.S. commercial insurance research database.

Methods

From the HealthCore Integrated Research Database (HIRD), we selected men ages 30 years or greater who were new users of TT during 2007 to 2015. We selected two comparison groups: (i) unexposed (matched 10:1) and (ii) new users of phosphodiesterase type 5 inhibitor (PDE5i). Incident prostate cancer was defined as diagnosis of prostate cancer within 4 weeks following prostate biopsy. Propensity scores and inverse probability of treatment weights were used in Poisson regression models to estimate adjusted incidence rates, incidence rate ratios (IRR), and 95% confidence intervals (CI). Subgroup analyses include

SUBMITTER: Cook MB 

PROVIDER: S-EPMC6954307 | biostudies-literature | 2020 Jan

REPOSITORIES: biostudies-literature